Safety and efficacy of s-citalopram in patients with co-morbid major depression and diabetes mellitus

Neuropsychobiology

Volumn 54, Issue 4, 2007, Pages 208-214

  Amsterdam, Jay D ^a,b   Shults, Justine ^a   Rutherford, Nancy ^a   Schwartz, Stanley ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b The Science Center Philadelphia   (United States)

Author keywords

Diabetes mellitus; Glycosylated hemoglobin; Major depressive disorder; S Citalopram; Selective serotonin reuptake inhibitor

Indexed keywords

ANTIDEPRESSANT AGENT; ESCITALOPRAM; FRUCTOSAMINE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; SEROTONIN UPTAKE INHIBITOR; ZALEPLON; ZOLPIDEM;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMORBIDITY; DAYTIME SOMNOLENCE; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FRUCTOSAMINE BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HAMILTON SCALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSOMNIA; LIBIDO DISORDER; MAJOR DEPRESSION; MALE; NERVOUSNESS; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BLOOD GLUCOSE; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DIABETES MELLITUS; FEMALE; FRUCTOSAMINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34147190820     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100369     Document Type: Article

References (50)

1. Lustman PJ, Griffith LS, Clouse RE: Depression in adults with diabetes. Results of 5-yr follow-up study. Diabetes Care 1988;11:605-612.
2. Montano CB: Primary care issues related to the treatment of depression in elderly patients. J Clin Psychiatry 1999;60(suppl 20):45-51.
3. Stein MB, Cox BJ, Afifi TO, Belik SL, Sareen J: Does co-morbid depressive illness magnify the impact of chronic physical illness? A population-based perspective. Psychol Med 2006;36:587-596.
4. Katon WJ, Rutter C, Simon G, Lin EH, Ludman E, Ciechanowski P, Kinder L, Young B, Von Korff M: The association of comorbid depression with mortality in patients with type 2 diabetes. Diabetes Care 2005;28:2668-2672.
5. Lin EH, Katon W, Rutter C, Simon GE, Ludman EJ, Von Korff M, Young B, Oliver M, Ciechanowski PC, Kinder L, Walker E: Effects of enhanced depression treatment on diabetes self-care. Ann Fam Med 2006;4:46-53.
6. Gavard JA, Lustman PJ, Clouse RE: Prevalence of depression in adults with diabetes - an epidemiologic evaluation. Diabetes Care 1993;16:1167-1178.
7. Goodnick PJ, Hernandez M: Treatment of depression in comorbid medical illness. Expert Opin Pharmacother 2000;1:1367-1384.
8. Rubin RR, Knowler WC, Ma Y, Marrero DG, Edelstein SL, Walker EA, Garfield SA, Fisher EB: Depressive symptoms and antidepressant medicine use in diabetes prevention program participants. Diabetes Care 2005;28:830-837.
9. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ: The prevalence of comorbid depression in adults with diabetes. Diabetes Care 2001;24:1069-1078.
10. Lustman PJ, Clouse RE, Carney RM: Depression and the reporting of diabetes symptoms. Int J Psychiatry Med 1988;18:295-303.
11. Skaer TL, Robison LM, Sclar DA, Dickson WM, Kozma GM, Reeder CE: Use of antidepressant pharmacotherapy within the first year after diagnosis of diabetes mellitus: a study of a Medicaid population. Curr Ther Res Clin Exp 1999;60:415-422.
12. Goodnick PJ, Jimenez I, Kumar A: Sertraline in diabetic neuropathy: preliminary results. Ann Clin Psychiatry 1997;9:255-257.
13. Goodnick PJ, Kumar A, Henry JH, Buki VMV, Goldberg RB: Sertraline in coexisting major depression and diabetes mellitus. Psychopharmacol Bull 1997;33:261-264.
14. Gulseren L, Gulseren S, Hekimsoy Z, Mete L: Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients. Arch Med Res 2005;36:159-165.
15. Lustman PJ, Clouse RE, Nix BD, Freedland KE, Rubin EH, McGill JB, Williams MM, Gelenberg AJ, Ciechanowski PS, Hirsch IB: Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 2006;63:521-529.
16. Goodnick PJ, Henry JH, Buki VMV: Treatments of depression in patients with diabetes mellitus. J Clin Psychiatry 1995;56:128-136.
17. Lustman PJ, Griffith LS, Clouse RE, Freedland KE, Eisen SA, Rubin EH, Carney RM, McGill JB: Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Med 1997;59:241-250.
18. Ghaeli P, Shahsavand E, Mesbahi M, Kamkar MZ, Sadeghi M, Dashti-Khavidaki S: Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder. J Clin Psychopharmacol 2004;24:386-388.
19. Winokur A, Maislin G, Amsterdam JD: Insulin resistance after oral glucose tolerance testing in patients with major depression. Am J Psychiatry 1988;145:325-330.
20. Erenmemisoglu A, Ozdogan UK, Saraymen R, Tutus A: Effect of some antidepressants on glycaemia and insulin levels of normoglycaemic and alloxan-induced hyperglycaemic mice. J Pharmacy Pharmacol 1999;51:741-743.
21. Potter van Loon BJ, Radder JK, Frolich M, Krans HM, Zwinderman AH, Meinders AE: Fluoxetine increases insulin action in obese non-diabetic and in obese non-insulin-dependent diabetic individuals. Int J Obesity 1992;16:79-85.
22. 123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacoly (Berl) 2006;188:263-272.
23. Greenblatt DJ, Von Moltke LL, Harmatz JS, Shader RI: Human cytochromes and some newer antidepressants: Kinetics, metabolism and drug interactions. J Clin Psychopharmacol 1999;19(suppl 1):23S-35S.
24. American Psychiatric Association: Diagnostic and Statistical Manual, ed IV TR. Washington, American Psychiatric Association, 2000.
25. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
26. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition, with Psychotic Screen (SCID-I/P W/PSY SCREEN) . New York, Biometrics Research, New York State Psychiatric Institute, 2001.
27. Shults J, Chaganty NR: Analysis of serially correlated data using quasi-least squares. Biometrics 1998;54:1622-1630.
28. Chaganty NR, Shults J: On eliminating the asymptotic bias in the quasi-least squares estimate of the correlation parameter. J Stat Plan Inference 1999;76:127-144.
29. Rotnizky A, Jewell N: Hypothesis testing of regression parameters in semiparametric generalized linear models for cluster correlated data. Biometrika 1990;77:485-497.
30. Wang YG, Carey VJ: Working correlation misspecification, estimation and covariate design: implications for generalized estimating equation performance. Biometrika 2003;90:29-41.
31. Shults J, Mazurick C, Landis R: Analysis of repeated bouts of measurements in the framework of generalized estimating equations. Stat Med 2006;25:4114-4128.
32. Shults J, Morrow A: Use of quasi-least squares to adjust for two levels of correlation. Biometrics 2002;58:521-530.
33. Shults J, Whitt MC, Kumanyika S: Analysis of data with multiple sources of correlation in the framework of generalized estimating equations. Stat Med 2004;23:3209-3226.
34. Wright JH, Jacisin JJ, Radin NS, Bell RA: Glucose metabolism in unipolar depression. Br J Psychiatry 1978;132:386-393.
35. Amsterdam JD, Maislin G: Comparison of growth hormone response after clonidine and insulin hypoglycemia in affective illness. Biol Psychiatry 1990;28:308-314.
36. Amsterdam JD, Maislin G: Hormonal responses during insulin-induced hypoglycemia in manic-depressed, unipolar depressed and healthy control subjects. J Clin Endocrinol Metab 1991;73:541-548.
37. de Groot M, Jacobson AM, Samson JA, Welch G: Glycemic control and major depression in patients with type 1 and type 2 diabetes mellitus. J Psychosom Res 1999;46:425-435.
38. Marcus MD, Wing RR, Guire J, Blair EH, Jawad A: Lifetime prevalence of major depression and its effect on treatment outcome in obese type II diabetic patients. Diabetes Care 1992;15:253-255.
39. Rosenthal MJ, Fajardo M, Gilmore S, Morley JE, Naliboff BD: Hospitalization and mortality of diabetes in older adults: a 3-year prospective study. Diabetes Care 1998;21:231-235.
40. Ciechanowski PS, Katon WJ, Russo JE: Depression and diabetes: impact on depressive symptoms on adherence, function and costs. Arch Intern Med 2000;160:3278-3285. 41 de Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ: Association of depression and diabetes complications: a meta-analysis. Psychosom Med 2001;63:619-630.
41. Egede LE, Zheng D, Simpson K: Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes Care 2002;25:464-470.
42. Max MB, Culnane M, Schafer SC, Gracely RH, Walther DJ, Smoller B, Dubner R: Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1997;37:589-596.
43. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R: Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Eng J Med 1992;325:1250-1256.
44. Sindrup SH, Bjerre U, Dejgaard A, Brosen K, Aaes-Jorgensen T, Gram LF: The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992;52:547-552.
45. Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS: Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 2003;60:1284-1289.
46. Raskin J, Smith TR, Wong K, Pritchett YL, D'Souza DN, Iyengar S, Wernicke JF: Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. J Palliat Med 2006;9:29-40.
47. Malinin A, Oshrine B, Serebruany V: Treatment with selective serotonin reuptake inhibitors for enhancing wound healing. Med Hypotheses 2004;63:103-109.
48. Bambauer KZ, Soumerai SB, Adams AS, Mah C, Zhang F, McLaughlin TJ: Does antidepressant adherence have an effect on glycemic control among diabetic antidepressant users? Int J Psychiatry Med 2004;34:291-304.
49. Cheer SM, Goa KL: Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. Drugs 2001;61:81-110.
50. Beck AT, Ward CH, Mendelson M, Mock JE, Erbaugh JK: An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571.